Baidu
map

Ann Intern Med:治疗左室射血分数降低和QRS间期延长的老年患者 CRT-D优于ICD

2014-05-09 高晓方 译 医学论坛网

美国一项研究表明,在左室射血分数降低和QRS间期延长的老年患者中,与仅置入型心律转复除颤器(ICD)相比,心脏再同步除颤器(CRT-D)治疗与死亡和再住院风险降低相关。论文5月6日在线发表于《内科学文献》。此项研究共纳入7090例年龄大于65岁且置入CRT-D或ICD的患者;受试者均伴有左室射血分数降低(<35%)和QRS间期延长(≥120 ms)。对CRT-D和ICD治疗后患者转归加以评估

美国一项研究表明,在左室射血分数降低和QRS间期延长的老年患者中,与仅置入型心律转复除颤器(ICD)相比,心脏再同步除颤器(CRT-D)治疗与死亡和再住院风险降低相关。论文5月6日在线发表于《内科学文献》。

此项研究共纳入7090例年龄大于65岁且置入CRT-D或ICD的患者;受试者均伴有左室射血分数降低(<35%)和QRS间期延长(≥120 ms)。对CRT-D和ICD治疗后患者转归加以评估。评估指标包括3年以上的死亡、再住院和装置相关性并发症风险。

结果显示,与ICD治疗相比,CRT-D与死亡、全因再住院、心血管再住院和心衰再住院风险降低具有相关性,危险比(HR)分别为0.82、0.86、0.80和0.78,但CRT-D亦与装置相关性感染风险升高具有相关性,HR 1.90。在左束支阻滞和QRS间期≥150 ms的患者以及女性患者中,CRT-D相对于ICD治疗的心衰再住院风险降低更为显著。

原始出处:


Masoudi FA, Mi X, Curtis LH, Peterson PN, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Al-Khatib SM, Piccini JP, Qualls LG, Hernandez AF.Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study.Ann Intern Med. 2014 May 6;160(9):603-11. doi: 10.7326/M13-1879.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]
    2014-08-21 yilong5287542
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1700462, encodeId=270c1e0046221, content=<a href='/topic/show?id=49fa4801038' target=_blank style='color:#2F92EE;'>#左室射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48010, encryptionId=49fa4801038, topicName=左室射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccd530104305, createdName=liuxiaona, createdTime=Sun Sep 07 18:15:00 CST 2014, time=2014-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860454, encodeId=ba7e186045498, content=<a href='/topic/show?id=d064933e0b' target=_blank style='color:#2F92EE;'>#ICD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9337, encryptionId=d064933e0b, topicName=ICD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87f580, createdName=yilong5287542, createdTime=Thu Aug 21 10:15:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341459, encodeId=08d3134145994, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449231, encodeId=46c814492315b, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517127, encodeId=8b71151e127a3, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606181, encodeId=f9d816061819f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun May 11 09:15:00 CST 2014, time=2014-05-11, status=1, ipAttribution=)]

相关资讯

白天嗜睡—老年人心血管疾病的危险因素

一项最新的试验研究表明:白天过度嗜睡的健康老年人心血管疾病死亡率及总体死亡率较无嗜睡健康老年人增高。欧洲心脏病学会发言人称,只需简单地询问一下老年人是否有白天嗜睡的情况,就可以确定他是不是心血管疾病的高危人群,进而做出相应的积极随访治疗及预防措施。 白天过度嗜睡(Excessive daytimesleepiness,EDS)标准定义为:白天在安静或单调环境下,经常困乏嗜睡,并不分场合和时机

FICC 2014:2014年心血管病介入治疗进展

第八届北京五洲国际心血管病会议的最新进展专场上,首都医科大学附属北京安贞医院柳景华教授介绍了2013至2014年心血管疾病介入治疗的最新进展,内容包括以下几方面。 一、回顾2013年美国心脏病学会基金会(ACCF)/美国心脏学会(AHA)ST段抬高型心肌梗死(STEMI)处理指南  二、 解读2014年美国无现场

WCC 2014:关注发展中国家现状——霍勇

本次世界心脏病学大会(WCC2 014)主席中的中国身影颇令我们自豪,《中国医学论坛报》特采访了本次WCC的学术委员会主席、中华医学会心血管病学分会主任委员霍勇教授,请他带领我们走近WCC 2014。 会议内容:涵盖心血管多个领域 霍勇教授介绍,WCC是由世界心脏联盟(WHF)举办的、每两年一次的国际学术会议,关注全球范围内、尤其是发展中国家心脑血管疾病的防治。20

FDA不建议阿司匹林用于心血管疾病一级预防

5月2日,美国食品与药物管理局(FDA)发布警告,FDA在审查了当前数据后认为,当前证据并不支持无心血管事件人群常规应用阿司匹林用于心脏病发作的一级预防。警告称从未发生心血管事件的人群服用阿司匹林会增其胃出血和脑出血的风险。至于在何种情况下应用阿司匹林一级预防可获益尚未明确。FDA还指出,当前证据支持已有心脏病发作或卒中病史的心血管疾病人群用阿司匹林预防心脏病或卒中的再发,即二级预防,其获益大于出

ACR:PsA的心血管病疾病发病风险高于RA

在过去的十年中,许多研究发现,慢性炎性关节炎患者的心血管疾病(CVD)的患病率逐年升高,其CVD负担呈上升趋势。包括meta分析在内的观察性研究报告指出,CVD患者的死亡率比一般人群高出50%。 在类风湿关节炎(RA),心血管疾病的危险度可能与2型糖尿病患者相似。 在一项回顾性研究中发现,经性别调整后,银屑病关节炎患者(PsA)患充血性心力衰竭和外周血管炎的比例明显高于健康对照组。此外,加拿大的

WCC 2014:缩小人群健康差异,澳大利亚做出尝试

据本次世界心脏病学大会(WCC2014)上的研究显示,少数种族和社会经济地位较低的人群发生心血管疾病的风险较高。在亚太地区开展的几项研究显示,与非本土人群和社会经济地位较高的人群相比,这类人群更易处于较高的心血管总体风险,治疗预后较差,较易因心血管疾病死亡。 来自亚太多个国家和地区的研究数据颇令我们担忧。但令人欣喜的是,在本次WCC2014上已经出现了在政策层面解决健康不均衡的实例,这是卫生改革

Baidu
map
Baidu
map
Baidu
map